Holen Sie sich die Stockscreener-App
64.84
0.38%
0.215
Schlusskurs vom Vortag:
$64.63
Offen:
$63.83
24-Stunden-Volumen:
436.53K
Relative Volume:
0.23
Marktkapitalisierung:
$12.55B
Einnahmen:
$3.29B
Nettoeinkommen (Verlust:
$268.74M
KGV:
47.32
EPS:
1.3704
Netto-Cashflow:
$759.12M
1W Leistung:
-3.12%
1M Leistung:
+1.67%
6M Leistung:
+6.57%
1J Leistung:
+16.50%
1-Tages-Spanne:
$63.64
$65.31
1-Wochen-Bereich:
$63.64
$67.69
52-Wochen-Spanne:
$49.26
$70.98
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Firmenname
Biomarin Pharmaceutical Inc
Sektor
Branche
Telefon
(415) 506-6700
Adresse
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
64.84 | 12.51B | 3.29B | 268.74M | 759.12M | 1.3704 |
VRTX
Vertex Pharmaceuticals Inc
|
522.72 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.34 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,003.96 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.54 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.28 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Fortgesetzt | Morgan Stanley | Overweight |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-20 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2025-12-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | Herabstufung | Stifel | Buy → Hold |
| 2025-09-08 | Eingeleitet | H.C. Wainwright | Neutral |
| 2025-09-03 | Eingeleitet | Raymond James | Outperform |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-24 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-30 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-20 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Eingeleitet | Evercore ISI | Outperform |
| 2023-11-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-23 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-18 | Eingeleitet | UBS | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2023-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Eingeleitet | Citigroup | Neutral |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2022-10-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2022-04-25 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-09 | Hochstufung | Stifel | Hold → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-04 | Fortgesetzt | Guggenheim | Buy |
| 2021-03-01 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Herabstufung | Stifel | Buy → Hold |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Bestätigt | Citigroup | Buy |
| 2020-01-28 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-27 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-24 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-04-09 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Bestätigt | Stifel | Buy |
| 2018-08-03 | Bestätigt | Stifel | Buy |
Alle ansehen
Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten
BioMarin Announces Positive Results of Phase 3 VOXZOGO® Study in Hypochondroplasia Published in NEJM Evidence - Investing News Network
A drug helped children with a rare growth disorder grow 2.33 cm more per year - Stock Titan
Don't Ignore The Insider Selling In BioMarin Pharmaceutical - simplywall.st
3 Reasons to Avoid BMRN and 1 Stock to Buy Instead - Yahoo Finance
Royalty Deal Could Be A Big Development For BioMarin Stock (BMRN) - simplywall.st
Weekly Recap: TransCon CNP license and Alesta Therapeutics acquisition - TradingView
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: 37% Upside Potential Amid Robust Revenue Growth - DirectorsTalk Interviews
RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout - Stocktwits
BioMarin Pharmaceutical (BMRN), What Is Behind The Fresh Attention? - simplywall.st
BioMarin (BMRN) Secured 20% U.S. Royalties on Yuviwel. Is Monetizing a Rival Better than Blocking It? - Yahoo Finance
EVP At BioMarin Pharmaceutical Sells $1.16M Of Stock - Benzinga
Ascendis Pharma (ASND) Settles Patent Fight And Wins Canadian Yorvipath Reimbursement Backing - Yahoo Finance
BioMarin (NASDAQ: BMRN) legal chief unloads 17,557 shares - Stock Titan
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset - Eastern Progress
Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A TargetUltragenyx Pharmaceutical (NASDAQ:RARE) - Benzinga
Officer at BioMarin (NASDAQ: BMRN) plans sale of 17,557 shares - Stock Titan
BioMarin to Participate in Upcoming Investor Conferences - Yahoo Finance
Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (AXSM), BioMarin Pharmaceutical (BMRN) and Envista Holdings (NVST) - The Globe and Mail
CASI Pharmaceuticals (CASIF) sells Alesta stake to BioMarin, with possible future milestone payouts - Stock Titan
How BioMarin’s Navepegritide Settlement and Royalty Deal with Ascendis Could Shape BioMarin (BMRN) Investors - simplywall.st
Piper Sandler raises BioMarin stock price target on IP settlement By Investing.com - Investing.com South Africa
BioMarin To Get Royalties From Ascendis Under IP Settlement - Law360
Oppenheimer raises Ascendis Pharma stock price target on settlement - Investing.com
BioMarin announces global settlement with Ascendis - The Pharma Letter
BioMarin Completes Alesta Therapeutics Acquisition, Adding HPP Drug Candidate ALE1 - citybiz
BioMarin Announces Close of the Alesta Therapeutics Acquisition - Investing News Network
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects - Eastern Progress
Piper Sandler raises BioMarin stock price target on IP settlement - Investing.com
BioMarin completes acquisition of Alesta, making it a wholly owned subsidiary - TradingView
Canaccord reiterates BioMarin stock rating on Ascendis settlement By Investing.com - Investing.com Australia
Canaccord reiterates BioMarin stock rating on Ascendis settlement - Investing.com
BioMarin Secures Double-Digit Yuviwel Royalties In Settlement With Ascendis - insights.citeline.com
Ascendis Pharma (NASDAQ: ASND) strikes global YUVIWEL settlement with BioMarin - Stock Titan
Ascendis Pharma A/S and Biomarin Pharmaceutical Inc. Enter Binding Term Sheet for Global Settlement and License Agreement Related to Yuviwel and Navepegritide-Related Products - marketscreener.com
Morgan Stanley reiterates BioMarin stock rating on settlement value By Investing.com - Investing.com Nigeria
Ascendis to pay 20% Yuviwel royalties in patent settlement with BioMarin - Fierce Pharma
BioMarin Pharma gains with analyst upgrade, pat... - Pluang
Jefferies raises BioMarin stock price target on Ascendis settlement - Investing.com
Morgan Stanley reiterates BioMarin stock rating on settlement value - Investing.com
Raymond James raises BioMarin stock price target on patent settlement By Investing.com - Investing.com Nigeria
Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis - BioSpace
Stifel holds BioMarin stock rating, keeps $70 target on IP deal - Investing.com Nigeria
BioMarin and Ascendis Pharma Finalize Patent Settlement with Royalty License Agreement - Kalkine Media
Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday - Benzinga
Ascendis Pharma Stock (ASND) Soars 7% on a Settlement with BioMarin Pharmaceutical (BMRN) - TipRanks
Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes - Yahoo Finance
BioMarin stock jumps after Ascendis patent settlement deal By Investing.com - Investing.com Nigeria
BioMarin stock jumps after Ascendis patent settlement deal - Investing.com
BioMarin Licenses CNP Program to Ascendis With 20%/18% Royalties, Ends Patent Disputes - TradingView
Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide) - Yahoo Finance
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: Unpacking a 40.78% Potential Upside - DirectorsTalk Interviews
Finanzdaten der Biomarin Pharmaceutical Inc-Aktie (BMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):